Sinopharm Group Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Wanyong Lian

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.7yrs
Yönetim Kurulu ortalama görev süresi	4.2yrs

Son yönetim güncellemeleri

Recent updates

CEO

Wanyong Lian (53 yo)

less than a year

Görev süresi

Mr. Wanyong Lian has been the Head of the investment management department of CNPGC since February 2008. Mr. Lian has over 20 years of working experience, all of which is management experience. Mr. Lian wa...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Wanyong Lian	President & Executive Director	less than a year	Veri yok	Veri yok
Xiaojuan Li	Chief Financial Officer	3.7yrs	Veri yok	Veri yok
Yijian Wu	Secretary to the Board	5.9yrs	Veri yok	Veri yok

3.7yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: 1099 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Wanyong Lian	President & Executive Director	less than a year	Veri yok	Veri yok
Qiyu Chen	Non-Executive Vice Chairman	14.5yrs	Veri yok	Veri yok
Dongjiu Li	Non-Executive Director	3.4yrs	Veri yok	Veri yok
Xiaohui Guan	Chief Supervisor	3.4yrs	Veri yok	Veri yok
Tak Lung Wu	Independent Non-Executive Director	4.2yrs	CN¥350.00k	Veri yok
Peiyu Li	Independent Non-Executive Director	4.2yrs	CN¥350.00k	Veri yok
Bingxiang Zhao	Non-Executive Chairman	less than a year	Veri yok	Veri yok
Deyong Wen	Non-Executive Director	7.2yrs	Veri yok	Veri yok
Fangruo Chen	Independent Non-Executive Director	5.9yrs	CN¥350.00k	Veri yok
Rongli Feng	Non Executive Director	4.4yrs	Veri yok	Veri yok
Weifeng Yu	Independent Non-Executive Director	4.2yrs	CN¥350.00k	Veri yok
Peng Wang	Non-executive Director	1.2yrs	Veri yok	Veri yok

4.2yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1099 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.2 yıldır).

Sinopharm Group Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sinopharm Group Co. Ltd. Announces Change in President

Sinopharm Group Co. Ltd. Announces Management Changes

Sinopharm Group Co. Ltd. Approves Appointment of Guo Jinhong as Chief Supervisor

Sinopharm Group Co. Ltd. Announces Retirement of Ma Ping, A Non-Executive Director

Sinopharm Group Co. Ltd. Announces Resignation of Zhuo Fumin as Independent Non-Executive Director

Sinopharm Group Co. Ltd. Approves Board Appointments

Recent updates

New minor risk - Financial position

Third quarter 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.64 in 3Q 2023)

Sinopharm Group Co. Ltd. to Report Nine Months, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 21%

Second quarter 2024 earnings released: EPS: CN¥0.73 (vs CN¥0.81 in 2Q 2023)

Sinopharm Group Co. Ltd. Announces Change in President

Sinopharm Group Co. Ltd. Announces Management Changes

Second quarter 2024 earnings released

Sinopharm Group Co. Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Sinopharm Group Co. Ltd. Declares Final Dividend for the Fiscal Year Ended December 31, 2023, Payable on 13 August 2024

Upcoming dividend of CN¥0.87 per share

Full year 2023 earnings released: EPS: CN¥2.91 (vs CN¥2.74 in FY 2022)

Sinopharm Group Co. Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Dividend of CN¥0.87 announced

Full year 2023 earnings released: EPS: CN¥2.91 (vs CN¥2.73 in FY 2022)

Sinopharm Group Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: EPS: CN¥0.64 (vs CN¥0.70 in 3Q 2022)

Sinopharm Group Co. Ltd. to Report Nine Months, 2023 Results on Oct 27, 2023

Sinopharm Group Co. Ltd. Approves Appointment of Guo Jinhong as Chief Supervisor

Sinopharm Group Co. Ltd. Announces Retirement of Ma Ping, A Non-Executive Director

Second quarter 2023 earnings released: EPS: CN¥0.81 (vs CN¥0.72 in 2Q 2022)

New major risk - Financial position

Sinopharm Group Co. Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Sinopharm Group Co. Ltd. Approves Final Dividend for the Financial Year End 31 December 2022, Payable on 14 August 2023

Upcoming dividend of CN¥0.82 per share at 3.4% yield

Sinopharm Group Co. Ltd. Announces Resignation of Zhuo Fumin as Independent Non-Executive Director

Full year 2022 earnings released: EPS: CN¥2.73 (vs CN¥2.49 in FY 2021)

Sinopharm Group Co. Ltd. Approves Board Appointments

Third quarter 2022 earnings released

Sinopharm Group Co. Ltd. to Report Q3, 2022 Results on Oct 26, 2022

Second quarter 2022 earnings released

Sinopharm Group Co. Ltd. to Report First Half, 2022 Results on Aug 26, 2022

Now 22% undervalued

Now 20% undervalued

Sinopharm Group Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2021, Payable No Later Than 23 August 2022

Upcoming dividend of CN¥0.75 per share

Sinopharm Group Co. Ltd. Announces Executive Changes

Sinopharm Group Co. Ltd. Announces Resignation of Deng Jindong as Member of Audit Committee and Remuneration Committee of Board

Sinopharm Group Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 23 August 2022

Now 20% undervalued after recent price drop

Full year 2021 earnings released: EPS: CN¥2.49 (vs CN¥2.31 in FY 2020)

Sinopharm Group Co. Ltd. to Report Q1, 2022 Results on Apr 21, 2022

Sinopharm Group Co. Ltd., Annual General Meeting, Jun 23, 2022

Now 22% undervalued

Third quarter 2021 earnings released: EPS CN¥0.68 (vs CN¥0.75 in 3Q 2020)

Independent Chief Supervisor Yifang Wu has left the company

Boyu, Sinopharm Reportedly Among Bidders Shortlisted for Mundipharma China

Upcoming dividend of CN¥0.69 per share

Joint Company Secretary has left the company

Full year 2020 earnings released: EPS CN¥2.31 (vs CN¥2.11 in FY 2019)

Investor sentiment improved over the past week

Full year 2020 earnings released

Sinopharm Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day low: HK$17.72

Sinopharm Group Co. Ltd. Announces Chief Financial Officer Changes

New 90-day high: HK$19.88

Sinopharm Group Co., Ltd. Announces Board Appointments

Sinopharm Group Co., Ltd. Announces Board Changes

New 90-day high: HK$19.74

Third quarter earnings released

New 90-day low: HK$16.08

Sinopharm Group Co., Ltd. to Report Nine Months, 2020 Results on Oct 22, 2020

New 90-day low: HK$17.64

Sinopharm Group Co., Ltd. Appoints Management Team

Sinopharm Group Co., Ltd. Appoints Directors

First half earnings released

New 90-day low - HK$17.90

First half earnings released